Compare · ABSI vs ONMD
ABSI vs ONMD
Side-by-side comparison of Absci Corporation (ABSI) and OneMedNet Corp (ONMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and ONMD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ABSI is the larger of the two at $1.50B, about 53.0x ONMD ($28.3M).
- Over the past year, ABSI is up 71.1% and ONMD is down 81.5% - ABSI leads by 152.6 points.
- ONMD has been more active in the news (14 items in the past 4 weeks vs 6 for ABSI).
- ABSI has more recent analyst coverage (21 ratings vs 0 for ONMD).
PerformanceABSI+83.55%ONMD-81.52%
2025-10-17+0.00%2026-10-16
- Company
- Absci Corporation
- OneMedNet Corp
- Price
- -
- -
- Market cap
- $1.50B
- $28.3M
- 1M return
- -10.16%
- -28.46%
- 1Y return
- +71.09%
- -81.52%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 6
- 14
- Recent ratings
- 21
- 0
ABSI
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest ABSI
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- SEC Form 4 filed by Absci Corporation
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- CFO / CBO Jonasson Zachariah covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 2% to 483,144 units (SEC Form 4) (withholding obligation)
- Absci to Participate in Upcoming Investor Conferences
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
Latest ONMD
- OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals
- SEC Form 8-K filed by OneMedNet Corp
- SEC Form 4 filed by OneMedNet Corp
- SEC Form 4 filed by OneMedNet Corp
- SEC Form 4 filed by OneMedNet Corp
- SEC Form 4 filed by OneMedNet Corp
- OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form 424B3 filed by OneMedNet Corp
- OneMedNet Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits